Boehringer In­gel­heim bags a con­tract man­u­fac­tur­er, adding mus­cles for can­cer vac­cine, on­colyt­ic virus pro­grams

As Boehringer In­gel­heim grows its pipeline of next-gen can­cer ther­a­pies, it’s al­so beef­ing up the ca­pac­i­ty to re­fine and make them.

The phar­ma gi­ant is snap­ping up La­bor Dr. Merk & Kol­le­gen, a Ger­man con­tract de­vel­op­ment and man­u­fac­tur­ing or­ga­ni­za­tion that’s carved out a niche in vi­rol­o­gy. For Boehringer, that ex­per­tise will come in handy for the on­colyt­ic virus and can­cer vac­cine pro­grams they got from ac­quir­ing Vi­raTher­a­peu­tics and AMAL Ther­a­peu­tics.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.